About the Company
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NBY News
Q4 2023 NovaBay Pharmaceuticals Inc Earnings Call
Hello, and welcome to the NovaBay Pharmaceuticals fourth-quarter and full year 2023 financial results conference call. All participants will be in listen-only mode. (Operator Instructions). As a ...
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare ...
NovaBay Pharmaceuticals: Q4 Earnings Insights
NovaBay Pharmaceuticals NBY reported its Q4 earnings results on Tuesday, March 26, 2024 at 04:05 PM. Here's what investors need to know about the announcement. NovaBay Pharmaceuticals beat estimated ...
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended ...
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces that ...
NovaBay Pharmaceuticals To Sell DERMAdoctor Skincare Business - Quick Facts
NovaBay Pharmaceuticals, Inc. (NBY) has entered into an agreement to sell its DERMAdoctor skincare business including all product ...
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q4 2023 Earnings Call Transcript
NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q4 2023 Earnings Call Transcript March 26, 2024 NovaBay Pharmaceuticals, Inc. misses ...
NovaBay Pharmaceuticals Inc NBY
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
NovaBay Pharmaceuticals, Inc. (NBY) Q4 2023 Earnings Call Transcript
Hello and welcome to the NovaBay Pharmaceuticals Fourth Quarter and Full Year 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
NovaBay Pharmaceuticals Inc NBY
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
NovaBay Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...